Cargando…
When, why and how tumour clonal diversity predicts survival
The utility of intratumour heterogeneity as a prognostic biomarker is the subject of ongoing clinical investigation. However, the relationship between this marker and its clinical impact is mediated by an evolutionary process that is not well understood. Here, we employ a spatial computational model...
Autores principales: | Noble, Robert, Burley, John T., Le Sueur, Cécile, Hochberg, Michael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428820/ https://www.ncbi.nlm.nih.gov/pubmed/32821272 http://dx.doi.org/10.1111/eva.13057 |
Ejemplares similares
-
The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status
por: Bikle, Daniel D
Publicado: (2020) -
Very early orthodontic treatment: when, why and how?
por: SCHNEIDER-MOSER, Ute E. M., et al.
Publicado: (2022) -
Endoscopic step up: When and how
por: Jearth, Vaneet, et al.
Publicado: (2022) -
Host plants and insecticides shape the evolution of genetic and clonal diversity in a major aphid crop pest
por: Roy, Lise, et al.
Publicado: (2022) -
Modelling white matter with spherical deconvolution: How and why?
por: Dell'Acqua, Flavio, et al.
Publicado: (2018)